Effectiveness and Safety of Complete Decongestive Therapy of Phase I: A Lymphedema Treatment Study in the Greek Population.
cdt
greece
lymphedema
phase i
physical therapy
treatment
Journal
Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737
Informations de publication
Date de publication:
19 Jul 2020
19 Jul 2020
Historique:
entrez:
22
8
2020
pubmed:
22
8
2020
medline:
22
8
2020
Statut:
epublish
Résumé
Background Lymphedema is a chronic condition caused by a failure in the lymphatic system that most commonly occurs in the limbs. Complete decongestive therapy (CDT) is the gold standard for lymphedema management. Objective To evaluate the effectiveness and safety of complete decongestive therapy (CDT) of phase I in the Greek population with lymphedema. Methods The patients' demographic and clinical characteristics were recorded. CDT was implemented in all patients for 20 sessions in a four-week treatment period. The edema's (excess volume (EV) and percent of excess volume (PEV)) measurements were carried out four times in the treatment period, whereas the percent reduction of excess volume (PREV) was calculated at the end of phase I. Moreover, we recorded every infection, trauma of skin, and pain of limb during the treatment. Results One-hundred five patients with lymphedema were enrolled in the present study, of whom 31.4% had upper limb lymphedema and 68.6% had lower limb lymphedema. All patients with upper limb lymphedema had a secondary type while the corresponding proportion of patients with lower limb lymphedema was 58.3%. A significant reduction (p<0.001) between the pre-treatment and post-treatment values of EV and PEV was found for both upper and lower limb lymphedema. For patients with upper limb lymphedema, the average PREV was 66.5% (interquartile range, 57.3%-80.6%), whereas for patients with lower limb lymphedema, a 71.5% (interquartile range, 64.5%-80.7%) median value was measured. No side effects from the treatment were recorded during CDT. Conclusion The proper treatment of the CDT phase I ensures safety and a great reduction in edema in patients with lymphedema that predispose the success of phase II of CDT.
Identifiants
pubmed: 32821610
doi: 10.7759/cureus.9264
pmc: PMC7431294
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e9264Informations de copyright
Copyright © 2020, Michopoulos et al.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Am J Med. 2000 Sep;109(4):296-300
pubmed: 10996580
Lymphology. 2016 Dec;49(4):170-84
pubmed: 29908550
Gynecol Oncol. 2013 Oct;131(1):127-30
pubmed: 23906654
Phys Ther. 2007 Oct;87(10):1362-8
pubmed: 17684090
Cancer. 1998 Dec 15;83(12 Suppl American):2835-9
pubmed: 9874408
Lymphology. 2009 Jun;42(2):51-60
pubmed: 19725269
Cancer Epidemiol Biomarkers Prev. 2007 Apr;16(4):775-82
pubmed: 17416770
Ann Surg Oncol. 2007 Jun;14(6):1904-8
pubmed: 17342565
J Surg Oncol. 2008 Jun 1;97(7):572-7
pubmed: 18459131
J Eur Acad Dermatol Venereol. 2017 Nov;31(11):1930-1935
pubmed: 28662302
Arch Surg. 1998 Apr;133(4):452-8
pubmed: 9565129
Clin J Oncol Nurs. 2008 Dec;12(6):951-64
pubmed: 19064389
Int J Clin Oncol. 2007 Dec;12(6):463-8
pubmed: 18071866
J Surg Oncol. 2004 Mar 15;85(4):187-92
pubmed: 14991874
Int J Radiat Oncol Biol Phys. 2007 Mar 1;67(3):841-6
pubmed: 17175115
J Clin Oncol. 2009 Apr 20;27(12):2007-14
pubmed: 19289624
Lymphat Res Biol. 2009;7(2):97-100
pubmed: 19522679
Cancer. 2012 Apr 15;118(8 Suppl):2237-49
pubmed: 22488698
Mayo Clin Proc. 2005 Nov;80(11):1480-4
pubmed: 16295027
Plast Surg Nurs. 2012 Oct-Dec;32(4):173-7; quiz 178-9
pubmed: 23188150
Breast Cancer Res Treat. 2006 Jul;98(1):1-6
pubmed: 16752081
Lymphology. 2013 Jun;46(2):97-104
pubmed: 24354108
J Hand Surg Br. 1992 Aug;17(4):437-41
pubmed: 1402274
Breast. 2013 Oct;22(5):703-6
pubmed: 23321586
Cancer. 1998 Dec 15;83(12 Suppl American):2843-60
pubmed: 9874410